DOCSLIB.ORG

ASTMH Clinical Pre-Meeting Course

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ASTMH Clinical Pre-Meeting Course Clinical Pre-Meeting Course: Tropical Dermatology Saturday, October 27, 2018, Noon - 5 pm Sunday, October 28, 2018, 7 am – 4 pm Sheraton New Orleans, New Orleans, LA, United States This 1.5-day course offers an overview of Tropical Dermatology, an essential component of tropical medicine. The course is designed for clinicians who are already familiar with clinical tropical medicine, either from working in tropical environments or from seeing patients returning from the tropics. Saturday’s session is devoted to cutaneous leishmaniasis (the latest information about the rapidly changing epidemiology, diagnosis, management). Skin conditions will be reviewed from the standpoint of diagnosing and treating individual patients – and from managing skin diseases on a population basis. This course will use several didactic methods, including lectures, lively Jeopardy-style presentations, panel discussions, hands-on practice with methods to treat cutaneous leishmaniasis, and opportunities to view pathogens and skin diseases under microscopy. The target audience includes clinicians who want to develop a deeper understanding of cutaneous leishmaniasis and other skin diseases found in the tropics, and expand their knowledge and skills needed to provide optimal care for this population. Course Schedule Saturday, October 27 Noon – 12:15 pm Introduction – Course Scope and Goals Naomi Aronson, MD, Director, Infectious Disease Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States Scott A. Norton, MD, MPH, MSc, Chief of Dermatology, Children’s National Medical Center, and George Washington University School of Medicine & Health Sciences, Washington, DC, United States 12:15 pm – 12:45 pm Changes in the Epidemiology of Cutaneous Leishmaniasis Peter Hotez, MD, PhD, FASTMH, Dean, Baylor College of Medicine, National School of Tropical Medicine, Houston, Texas, United States 12:45 pm – 1:30 pm Jeopardy I: Leishmaniasis and its Mimics Naomi Aronson and Scott Norton Karolyn Wanat, MD, University of Iowa Hospital and Clinics, Iowa City, Iowa, United States 1:30 pm – 2 pm Diagnosis of Cutaneous Leishmaniasis Andrea Boggild, BSc, MSc, MD, FRCPC, Clinical Director, Tropical Disease Unit, Toronto General Hospital and University of Toronto, Toronto, ON, Canada 2 pm – 2:45 pm Management of Old World Cutaneous Leishmaniasis Pierre Buffet, MD, PhD, UPMC-Service de Parasitologie Mycologie, Université Paris Descartes, Paris, France 2:45 pm – 3 pm ThermoMed/Cryotherapy Demonstration (extends into break) Naomi Aronson, Pierre Buffet and Scott Norton 3 pm – 3:15 pm Coffee Break 3:15 pm – 3:45 pm Management of New World Cutaneous Leishmaniasis Naomi Aronson 3:45 pm – 4:15 pm Mucosal Leishmaniasis: Pathology and Immunology Guide Management Edgar Carvalho, MD, PhD, Federal University of Bahia, Salvador, Brazil 4:15 pm – 4:45 pm The Future of Global Treatment of Cutaneous Leishmaniasis Byron Arana, MD, PhD, Cutaneous Leishmaniasis Team Lead, Drugs for Neglected Diseases Initiative, Geneva, Switzerland 4:45 pm – 5 pm Questions and Panel Discussion Byron Arana, Naomi Aronson, Andrea Boggild, Pierre Buffet, Edgar Carvalho, Peter Hotez 5 pm Attendee Reception Sunday, October 28 7 am – 8 am Networking Breakfast 8 am – 8:30 am Introduction to Tropical Dermatology Scott Norton 8:30 am – 9 am Sentinel Presentations of Reportable Diseases Karolyn Wanat 9 am – 9:30 am Skin Conditions Among Refugees, Migrants and Adoptees Alexia Knapp, MD, HealthPartners Medical Group and University of Minnesota Global Health Pathway, Saint Paul, Minnesota, United States 9:30 am – 10:30 am Jeopardy II: Drugs, Bugs, Lumps and Bumps Aileen Y. Chang, MD, Dermatology Department, University of California San Francisco, San Francisco, California, United States L. Claire Fuller, MBBS, Dermatology Department, Chelsea & Westminster Hospital – NHS, London, United Kingdom Wingfield E. Rehmus, MD, Dermatology Department, University of British Columbia, Vancouver, BC, Canada Karolyn Wanat 10:30 am – 10:45 am Coffee Break 10:45 am – 11:15 am HIV Dermatology Esther E. Freeman, MD, PhD, Department of Dermatology, Massachusetts General Hospital, Cambridge, Massachusetts, United States 11:15 am – 11:45 am Dermatologic Diseases Associated with Environmental Changes and Natural Disasters Justin P. Bandino, MD, Dermatology Department, San Antonio Military Medical Center, San Antonio, Texas, United States 11:45 pm – 12:15 pm Dermatologic Formulary and Diagnostics in Resource Poor Settings Scott Norton 12:15 pm – 1:30 pm Lunch (on your own) Demonstration of Dermatologic Diagnostic and Therapeutic Methods (extends into lunch) Naomi Aronson, Justin Bandino, Alexia Knapp, Scott Norton 1:30 pm – 2:15 pm Dermatologic Neglected Tropical Diseases: The Most N of the NTDs Erin H. Amerson, MD, Dermatology Department, University of California San Francisco, San Francisco, California, United States Aileen Y. Chang 2:15 pm – 2:45 pm Skin Disorders Associated with Adventure Travel and Eco-Tourism Wingfield E. Rehmus 2:45 pm – 3:45 pm Jeopardy III: Parasites Lost (and other Communicable Conditions) Erin Amerson, Esther Freeman, Scott Norton, Karolyn Wanat 3:45 pm – 4 pm Questions and Panel Discussion Naomi Aronson, Scott Norton and Speakers 4 pm Course Adjourns .
Load more

Recommended publications
  • TESTIMONY Peter J. Hotez MD, Phd President, Sabin Vaccine Institute
    TESTIMONY Peter J. Hotez MD, PhD President, Sabin Vaccine Institute “The Growing Threat of Cholera and Other Diseases in the Middle East” Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations Committee on Foreign Affairs United States House of Representatives March 2, 2016 Mr. Chairman and Members of the Subcommittee, thank you for the opportunity to speak with you today. I am Peter Hotez, a biomedical scientist and pediatrician. I am the dean of the National School of Tropical Medicine at Baylor College of Medicine and also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics based at the Texas Medical Center in Houston. I am also past president of the American Society of Tropical Medicine and Hygiene, and currently serve as President of the Sabin Vaccine Institute, a non-profit which develops vaccines for neglected tropical diseases (NTDs) through a product development partnership (PDP) model. This year I am also serving as US Science Envoy for the State Department and White House Office of Science and Technology Policy focusing on the urgency to develop vaccines for diseases that are emerging in the Middle East and North Africa due to the breakdowns in health systems in the ISIS occupied conflict zones in Syria, Iraq, Libya, and also Yemen. In my submitted written testimony I highlighted some of the successes in US global health policy, many of which can be attributed to the hard work of this Subcommittee working hand in glove with two presidential administrations since 2000. I cite evidence from the Global Burden of Disease Study (GBD) that brings together hundreds of scientists - I am also a part of this - who are measuring the impact of large scale global health programs.
    [Show full text]
  • 1999 Annual Report
    1999 1999 BANBURY CENTER DIRECTOR'S REPORT The Banbury Center program continues to be as eclectic and exciting as ever. The year was filled with more meetings than ever before-a record 23 of them! Laboratory scientists used the Center for seven in-house meetings, and local community groups came here on eight occasions. Together with the five neurobiology courses, there was hardly a week when the Center was not in use. Not surprisingly, 1999 was also a record year for the number of visitors to Banbury Center: 667 par­ ticipants attended the 23 meetings. The demographics of our participants remain much the same: 25% of visitors to Banbury Center came from abroad, with the United Kingdom, Germany, and Canada lead­ ing the way. Of the American scientists, those from New York, Massachusetts, and California together accounted for more than 32% of the total. However, participants were drawn from no fewer than 42 states. This is the first year that we have been able to use the Meier House to accommodate participants, which proved to be wonderful. Now the number of participants that we can house on the Banbury estate matches the number we can have in the Conference Room-we do not have to transport peo­ ple between the Center and the main campus. Biological and biomedical research is becoming ever more interdisciplinary, and as it does so, it also becomes ever more difficult to categorize the topics of Banbury Center meetings. A meeting may deal with the same phenomenon in a range of organisms, or many different strategies may be used to study one phenomenon in a single species.
    [Show full text]
  • Sabin in the News Recent Scientific Articles Sabin Vaccine Institute
    Home About Us News & Resources Support Sabin Sabin in the News October 2011 The Sabin Report | Volume 13 Issue 2 New York Times article featuring Dr. Peter Hotez's new study on increased Sabin Vaccine Institute Establishes a Houston prevalence of NTDs in Europe. Office Drs. Ciro de Quadros and In September 2011, the Zulfiqar Bhutta highlight Sabin Vaccine Institute the dire need for a dengue established offices in vaccine in an opinion Houston, Texas in the piece for GlobalPost. heart of the city's Texas Medical Center (TMC). The In an interview on Voice of new facilities will house the America Dr. Peter Hotez Sabin Vaccine Institute & focused on NTDs in Sub- Texas Children's Hospital Saharan Africa. Center for Vaccine Development, which will be An article by Dr. Neeraj operated in partnership Mistry was featured in a with Baylor College of special supplemental Medicine Department of section of the USA today, Pediatrics. Sabin Dr. Hotez and team at Sabin's new Houston facility titled "Neglected Diseases President, Dr. Peter J. in Developing Nations". Hotez will direct the new center. In an op-ed for the Houston Chronicle, Dr. The new space includes offices and laboratories through which the Peter Hotez writes about Sabin Vaccine Institute Product Development Partnership (PDP) will the establishment of the advance and strengthen its collaborative work in the field of vaccine new School of Tropical biotechnology. The change is the result of a year-long plan to expand Medicine at Baylor College the scope and depth of the Sabin PDP's partnership and to enhance of Medicine.
    [Show full text]
  • The Neglected Tropical Diseases: the Ancient Afflictions of Stigma And
    3 The Neglected Tropical Diseases: The Ancient Affl ictions of Stigma and Poverty and the Prospects for their Control and Elimination Peter Hotez, Eric Ottesen, Alan Fenwick, and David Molyneux 1. Introduction The World Health Organizations and other international health agencies iden- tify a select group of 13 tropical infections as the neglected tropical diseases (NTDs). These diseases, which include leprosy, kala-azar, river blindness, guinea worm, schistosomiasis, hookworm and lymphatic fi lariasis, strike the world’s poorest people living in remote and rural areas of low-income countries in Sub-Saharan Africa, Asia and the Americas. They infl ict suffering by causing life-long disabili- ties, disfi gurement, reduced economic productivity, and social stigma (WHO, 2003). Unlike better-known global health threats such as HIV-AIDS, malaria, and tuber- culosis, the NTDs do not receive enough international attention. Instead, they are neglected diseases among forgotten people found only in the setting of geographic isolation and intense poverty (Molyneux, 2004). Impoverished and marginalized populations with the NTDs represent the lowest priority markets for U.S. and European pharmaceutical manufacturers. The NTDs do not occur in the industrialized world or even among the substantial wealthy and middle-classes in developing countries. They are not a signifi cant health risk for foreign travelers or the military. This is in contrast to the more substantial com- mercial markets for HIV-AIDS, malaria and tuberculosis (“the big three”). The recent creation of massive funding schemes for the big three, such as The Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the U.S.
    [Show full text]
  • TRANSCRIPT Peter Hotez, M.D., Ph.D. Dean, National School Of
    TRANSCRIPT Peter Hotez, M.D., Ph.D. Dean, National School of Tropical Medicine Professor, Departments of Pediatrics and Molecular Virology & Microbiology Baylor College of Medicine Endowed Chair of Tropical Pediatrics, Texas Children’s Hospital President, Sabin Vaccine Institute Helene D. Gayle, M.D., M.P.H. President and CEO CARE USA William Foege, M.D., M.P.H. Senior Fellow, Health Policy, Carter Center Senior Fellow, Global Health Program, Gates Foundation Emeritus Presidential Distinguished Professor of International Health Emory University Meeting 20, Session 2 February 5, 2015 Washington, DC SESSION 2: PUBLIC HEALTH PERSPECTIVES ON THE CURRENT EBOLA EPIDEMIC IN WEST AFRICA DR. WAGNER: All right, Commissioners. Let’s—since our guests are ready to go, let’s the rest of us also do that. Delighted to welcome our next panel, and we’ll use the same process as before. One by one, we will introduce you and ask you to speak, and then we’ll introduce and move each successive—to each successive panelist and hold all questions until all three of you have had a chance to speak. This session, we’ve asked our panelists to help us advise us on the public health perspectives on the current Ebola epidemic in Western Africa. And we will begin with Dr. Peter Hotez. Dr. Hotez is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine. He also heads the new section of pediatric tropical medicine and is Texas Children’s Hospital Endowed Chair of Tropical Pediatrics. He’s the President of the Sabin Vaccine Institute, is an internationally recognized physician-scientist in neglected tropical diseases and vaccine development.
    [Show full text]
  • What Contributes to COVID-19 Vaccine Hesitancy in Black Communities, and How Can It Be Addressed?
    Research Report C O R P O R A T I O N LAURA M. BOGART, LU DONG, PRIYA GANDHI, SAMANTHA RYAN, TERRY L. SMITH, DAVID J. KLEIN, LUCKIE ALEXANDER FULLER, BISOLA O. OJIKUTU What Contributes to COVID-19 Vaccine Hesitancy in Black Communities, and How Can It Be Addressed? ecent polls show that Black Americans are less willing than Americans of other races or ethnicities to be vaccinated for COVID-19, even after the November 2020 announcements by pharmaceutical companies Pfizer and BioNTech and Moderna about their vaccines’ R 1 high efficacy. For example, responses to a November 2020 poll of an online survey panel found that 42 percent of Black Americans, versus 63 percent of Hispanic or Latinx Americans and 61 percent of White Americans, said that they would definitely or probably get vaccinated.2 A December 2020 nationally representative telephone poll found that 35 percent of Black adults said KEY FINDINGS that they would definitely not or Q A survey of a nationally representative sample of 207 Black Ameri- probably not get vaccinated3—and cans conducted in late 2020 found high levels of vaccine hesitancy about half of those who did not and mistrust of COVID-19 vaccines in the overall sample, as well as want to get vaccinated cited mistrust among health care workers in particular. of vaccines as well as worry about Q Those who expressed vaccine hesitancy also showed high levels getting COVID-19 from the vaccine of overall mistrust, concerns about potential harm and side effects, as main reasons. Evidence thus and lack of confidence in vaccine effectiveness and safety.
    [Show full text]
  • Peter Hotez, M.D., Ph.D. Biography
    Peter Hotez, MD, PhD, FASTMH, FAAP Peter J. Hotez, M.D., Ph.D., is professor of pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine where he is also chief of a new Section of Pediatric Tropical Medicine and founding Dean of the National School of Tropical Medicine. In addition Prof. Hotez is the Texas Children's Hospital Endowed Chair of Tropical Pediatrics, and president of the Sabin Vaccine Institute. He will lead the new Sabin vaccine development program at Texas Children's Hospital and Baylor College of Medicine. He moves to BCM and Texas Children's from The George Washington University, where he has served as a Distinguished Research Professor and the Walter G. Ross Professor and Chair of the Department of Microbiology, Immunology and Tropical Medicine. Dr. Hotez is an internationally-recognized clinician and investigator in neglected tropical diseases and vaccine development. Diseases he studies include hookworm, schistosomiasis, Chagas disease, leishmaniasis, and malaria, among others, impacting hundreds of millions of children and adults worldwide. He obtained his undergraduate degree in molecular biophysics from Yale University in 1980, followed by a Ph.D. degree in biochemical parasitology from Rockefeller University in 1986 and a medical degree from Cornell University in 1987. He completed pediatric residency training at Massachusetts General Hospital from 1987 to 1989 and postdoctoral fellowship training in infectious diseases and molecular parasitology at Yale from 1989 to 1991. Dr. Hotez joined the Yale faculty as an assistant professor of pediatrics in 1992. He became an associate professor in 1995 before moving to the George Washington University as professor and chair in 2000.
    [Show full text]
  • COVID-19 Vaccine Development, Strategy and Implementation
    Symposium: Vaccines and Global Health: COVID-19 Vaccine Development, Strategy and Implementation The Program in Vaccine Education at the Columbia University Vagelos College of Physicians & Surgeons’ mission is to educate medical students and to inform health care professionals, public health experts, academic, government and industry researchers, policy makers, global health non-governmental organizations, journalists, and the general public as to the cutting-edge advances and challenges in modern vaccine development. The Columbia University convenors are Drs. Lawrence Stanberry (Co-Director, PVE), Philip LaRussa (Co-Director, PVE), Wilmot James (Associate Director, PVE), and Marc Grodman (Special Advisor, PVE). We have put together a group of 25 outstanding speakers who have been intimately involved with all aspects of COVID-19 vaccine development, strategy, and implementation. We are delighted to present this five-day virtual symposium at the cusp of the world’s transition to controlling the COVID-19 pandemic. Monday, February 22 National, Regional and Global Response to an Unprecedented Challenge 12:00-12:10 Welcome: Lee Bollinger, JD – President, Columbia University 12:10-12:15 Moderator: Lawrence R. Stanberry, MD, PhD – Director of the Programs in Global Health, Columbia University Vagelos College of Physicians and Surgeons 12:15-12:45 Keynote: Sir Jeremy Farrar, BSc, MBBS, PhD – Director, Wellcome Trust The Role of the Wellcome Trust in COVID-19 Vaccine Preparedness 12:45-1:30 Speakers: - Shabir Madhi, MBChB, MMed, FCPaeds PhD – Professor of Vaccinology, University of the Witwatersrand – A South African perspective on vaccine preparedness and availability. - Nancy Messonnier, MD – Director, National Center for Immunization and Respiratory Diseases, US CDC – A US CDC perspective on vaccine preparedness and availability.
    [Show full text]
  • Ending the Neglect of Neglected Tropical Diseases
    Policy Brief FEBRUARY 2010 BY RICHARD SKOLNIK ENDING THE NEGLECT OF AND AMBAREEN AHMED NEGLECTED TROPICAL DISEASES More than 1 billion people, about one-sixth of the people worldwide; whipworm (trichuriasis) affects world’s population, are infected with one or more 604 million; and hookworm affects 576 million. of 13 “neglected tropical diseases” (NTDs).1 These The four other most common NTDs include: schis- NTDs are diseases of diseases are the most common afflictions of the tosomiasis (snail fever), affecting about 200 million poverty, affecting nearly world’s poorest people (see table). people; lymphatic filariasis (elephantiasis), which everyone in the “bottom affects 120 million people; blinding trachoma, billion” of the world’s NTDs have a terrible impact on health, impede poorest people. affecting more than 80 million people; and oncho- child growth and development, harm pregnant cerciasis (river blindness), which affects almost 40 women, and often cause long-term debilitating million people. illnesses. They cause an extraordinary amount of ill health, disability and disfigurement, and are The impact of NTDs on health globally can best often deadly. As a result, those who suffer from be understood by measuring the years of healthy NTDs are frequently shunned by their families and life lost from NTDs due to illness, disability, and their communities. In addition, people with these premature death. A commonly used measure of diseases are often unable to work productively, these healthy life years lost is the DALY, which 41MILLION leading to enormous economic losses for them, stands for Disability Adjusted Life Year. A num- The number of people their families, and for the nations in which they live.
    [Show full text]
  • Peter Hotez - Wikipedia
    Peter Hotez - Wikipedia https://en.wikipedia.org/wiki/Peter_Hotez Peter Hotez Peter Jay Hotez (born May 5, 1958) is an American scientist, pediatrician, and advocate in the fields of global Peter Hotez health, vaccinology, and neglected tropical disease control. He serves as founding dean of the National School of Tropical Medicine, Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, where he is also Director of the Texas Children's Hospital Center for Vaccine Development and Texas Children’s Hospital Endowed Chair in Tropical Pediatrics, and University Professor of Biology at Baylor University.[1][2] Hotez served previously as President of the American Society of Tropical Medicine and Hygiene and is a founding Editor- in-Chief of PLOS Neglected Tropical Diseases. He is also the co-director of Parasites Without Borders, a global nonprofit organization with a focus on those suffering from parasitic diseases in subtropical environments. Contents Born Peter Jay Hotez Early life and education May 5, 1958 Research and career Hartford, Connecticut, Early research U.S. Neglected tropical diseases (NTDs) Nationality American Vaccine development Alma mater Yale University (BA) COVID-19 response Weill Cornell Awards and memberships Medical College Publications and media (MD) References Rockefeller University External links (PhD) Scientific career Fields Vaccinology, Early life and education neglected tropical disease control, public Hotez was born in Hartford, Connecticut to a Jewish policy, global health
    [Show full text]
  • ASTMH Clinical Pre-Meeting Course
    Clinical Pre-Meeting Course: Tropical Dermatology Saturday, October 27, 2018, Noon - 5 pm Sunday, October 28, 2018, 7 am – 4 pm Sheraton New Orleans, New Orleans, LA, United States This 1.5-day course offers an overview of Tropical Dermatology, an essential component of tropical medicine. The course is designed for clinicians who are already familiar with clinical tropical medicine, either from working in tropical environments or from seeing patients returning from the tropics. Saturday’s session is devoted to cutaneous leishmaniasis (the latest information about the rapidly changing epidemiology, diagnosis, management). Skin conditions will be reviewed from the standpoint of diagnosing and treating individual patients – and from managing skin diseases on a population basis. This course will use several didactic methods, including lectures, lively Jeopardy-style presentations, panel discussions, hands-on practice with methods to treat cutaneous leishmaniasis, and opportunities to view pathogens and skin diseases under microscopy. The target audience includes clinicians who want to develop a deeper understanding of cutaneous leishmaniasis and other skin diseases found in the tropics, and expand their knowledge and skills needed to provide optimal care for this population. Course Schedule Saturday, October 27 Noon – 12:15 pm Introduction – Course Scope and Goals Naomi Aronson, MD, Director, Infectious Disease Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States Scott A. Norton, MD, MPH, MSc,
    [Show full text]
  • The Sabin Report | Volume 11 Issue 2 Is Winner of the 2009 Albert B
    Dr. Rino Rappuoli The Sabin Report | Volume 11 Issue 2 is Winner of the 2009 Albert B. Sabin Gold Medal Global Network Announces More than Four Million Award Women and Children Dewormed in Rwanda for Approximately 30 Cents Per Person The Access Project, a partner of the Global Network, the Rwandan government and other international partners worked with locally trained community health providers in Rwanda to de-worm more than four million women and children during the country's Mother and Child Health Week in March. Albendazole was administered to a targeted population of On April 28th, Rino children under five, school-age children, and post-partum women, to Rappuoli, PhD was treat for soil-transmitted helminthes (STHs) commonly known as presented with the intestinal worms, reaching 95.2% of the target population at Albert B. Sabin Gold approximately 30 cents per person. Additionally, in high prevalence Medal Award. This areas, children were treated with praziquantel for schistosomiasis, a prestigious award parasitic disease carried by fresh water snails. Vitamin A, recognizes a immunizations, family planning services and health education messages distinguished member were also delivered throughout the country. of the research Read press release here community who has made extraordinary contributions in the field South Africa Announces of vaccinology or a complementary field. Introduction of Pneumococcal The Medal is the Vaccine at 4th Regional highest scientific honor Pneumococcal Symposium given by the Sabin Vaccine Institute and During the 4th Regional Pneumococcal commemorates the Symposium held in South Africa on March legacy of the late Dr. 2-3, South African Deputy Minister of Albert B.
    [Show full text]